
Semaglutide Shows Major Benefits in PAD: STRIDE
Semaglutide, a GLP-1 agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, the drug significantly improved walking distance, symptoms like pain, and quality of life in …